Skip to main content
Top
Published in: Lung 2/2020

01-04-2020 | Glibenclamide | ACUTE LUNG INJURY

Nicorandil, a KATP Channel Opener, Attenuates Ischemia–Reperfusion Injury in Isolated Rat Lungs

Authors: Kyoko Abe, Takashi Horiguchi, Keiji Enzan, Yoko Masaki, Toshiaki Nishikawa, Tetsu Kimura

Published in: Lung | Issue 2/2020

Login to get access

Abstract

Purpose

Nicorandil is a hybrid between nitrates and KATP channel opener activators. The aim of this study was to evaluate the nicorandil’s effects on ischemia–reperfusion (IR) lung injury and examine the mechanism of its effects.

Methods

Isolated rat lungs were divided into 6 groups. In the sham group, the lungs were perfused and ventilated for 150 min. In the IR group, after perfusion and ventilation for 30 min, they were interrupted (ischemia) for 60 min, and then resumed for 60 min. In the nicorandil (N) + IR group, nicorandil 6 mg was added before ischemia (nicorandil concentration was 75 µg ml−1). In the glibenclamide + N + IR group, the L-NAME (Nω-Nitro-l-arginine methyl ester) + N + IR group and ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one) + N + IR group, glibenclamide 3 µM, L-NAME 100 µM, and ODQ 30 µM were added 5 min before nicorandil administration, respectively. We measured the coefficient of filtration (Kfc) of the lungs, total pulmonary vascular resistance, and the wet-to-dry lung weight ratio (WW/DW ratio).

Results

Kfc was significantly increased after 60 min reperfusion compared with baseline in the IR group, but no change in the sham group. An increase in Kfc was inhibited in the N + IR group compared with the IR group (0.92 ± 0.28 vs. 2.82 ± 0.68 ml min−1 mmHg−1 100 g−1; P < 0.01). Also, nicorandil attenuated WW/DW ratio was compared with IR group (8.3 ± 0.41 vs. 10.9 ± 2.5; P < 0.05). Nicorandil’s inhibitory effect was blocked by glibenclamide and ODQ (P < 0.01), but not by L-NAME.

Conclusions

Nicorandil attenuated IR injury in isolated rat lungs. This protective effect appears to involve its activation as KATP channel opener as well as that of the sGC-cGMP pathway.
Literature
1.
go back to reference Suzuki Y, Cantu E, Christie JD (2007) Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Cirt Care Med 175:507–513CrossRef Suzuki Y, Cantu E, Christie JD (2007) Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Cirt Care Med 175:507–513CrossRef
2.
go back to reference Daud SA, Yusen RD, Meyers BF et al (2007) Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Cirt Care Med 175:507–513CrossRef Daud SA, Yusen RD, Meyers BF et al (2007) Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Cirt Care Med 175:507–513CrossRef
3.
go back to reference Taira N (1989) Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 63:18J–24JCrossRef Taira N (1989) Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 63:18J–24JCrossRef
4.
go back to reference IONA Study Group (2002) Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359:1269–1275CrossRef IONA Study Group (2002) Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359:1269–1275CrossRef
5.
go back to reference Yamashita M, Schmid RA, Fujino S, Cooper JD, Patterson GA (2008) Nicorandil, a potent adenosine triphosphate-sensitive potassium-channel opener, ameliorates lung allograft reperfusion injury. J Thorac Cardiovasc Surg 112:1307–1314CrossRef Yamashita M, Schmid RA, Fujino S, Cooper JD, Patterson GA (2008) Nicorandil, a potent adenosine triphosphate-sensitive potassium-channel opener, ameliorates lung allograft reperfusion injury. J Thorac Cardiovasc Surg 112:1307–1314CrossRef
6.
go back to reference Liu R, Ishibe Y, Ueda M (2000) Isoflurane-sevoflurane adminstration before ischemia attenuates ischemia–reperfusion-induced injury in isolated rat lungs. Anesthesiology 92:833–840CrossRef Liu R, Ishibe Y, Ueda M (2000) Isoflurane-sevoflurane adminstration before ischemia attenuates ischemia–reperfusion-induced injury in isolated rat lungs. Anesthesiology 92:833–840CrossRef
7.
go back to reference Drake R, Gaar KA, Taylor AE (1978) Estimation of the filtration coefficient of pulmonary exchange vessels. Am J Physiol 234:H266–274PubMed Drake R, Gaar KA, Taylor AE (1978) Estimation of the filtration coefficient of pulmonary exchange vessels. Am J Physiol 234:H266–274PubMed
8.
go back to reference Khimenko PL, Moore TM, Taylor AE (1995) ATP-sensitive K+ channels are not involved in ischemia-reperfusion lung endothelial injury. J Appl Physiol 79:554–559CrossRef Khimenko PL, Moore TM, Taylor AE (1995) ATP-sensitive K+ channels are not involved in ischemia-reperfusion lung endothelial injury. J Appl Physiol 79:554–559CrossRef
9.
go back to reference Kandilci HB, Gümüşel B, Demiryürek AT, Lippton H (2006) Preconditioning modulates pulmonary endothelial dysfunction following ischemia-reperfusion injury in the rat lung: role of potassium channels. Life Sci 79:2172–2178CrossRef Kandilci HB, Gümüşel B, Demiryürek AT, Lippton H (2006) Preconditioning modulates pulmonary endothelial dysfunction following ischemia-reperfusion injury in the rat lung: role of potassium channels. Life Sci 79:2172–2178CrossRef
10.
go back to reference Pieper GM, Gross GJ (1992) EMD 52692 (bimakalim), a new potassium channel opener, attenuates luminol-enhanced chemiluminescence and superoxide anion radical formation by zymosan-activated polymorphonuclear leukocytes. Immunopharmacology 23:191–197CrossRef Pieper GM, Gross GJ (1992) EMD 52692 (bimakalim), a new potassium channel opener, attenuates luminol-enhanced chemiluminescence and superoxide anion radical formation by zymosan-activated polymorphonuclear leukocytes. Immunopharmacology 23:191–197CrossRef
11.
go back to reference Chetham PM, Sefton WD, Bridges JP, Stevens T, McMurtry IF (1997) Inhaled nitric oxide pretreatment but not posttreatment attenuates ischemia-reperfusion-induced pulmonary microvascular leak. Anesthesiology 86:895–902CrossRef Chetham PM, Sefton WD, Bridges JP, Stevens T, McMurtry IF (1997) Inhaled nitric oxide pretreatment but not posttreatment attenuates ischemia-reperfusion-induced pulmonary microvascular leak. Anesthesiology 86:895–902CrossRef
12.
go back to reference Egan TM, Hoffmann SC, Sevala M, Sadoff JD, Schlidt SA (2006) Nitroglycerin reperfusion reduces ischemia-reperfusion injury in non-heart-beating donor lungs. J Heart Lung Transplant 25:110–119CrossRef Egan TM, Hoffmann SC, Sevala M, Sadoff JD, Schlidt SA (2006) Nitroglycerin reperfusion reduces ischemia-reperfusion injury in non-heart-beating donor lungs. J Heart Lung Transplant 25:110–119CrossRef
13.
go back to reference Takashima S, Koukoulis G, Inokawa H, Sevala M, Egan TM (2006) Inhaled nitric oxide reduces ischemia–reperfusion injury in rat lungs from non-heart-beating donors. J Thorac Cardiovasc Surg 132:132–139CrossRef Takashima S, Koukoulis G, Inokawa H, Sevala M, Egan TM (2006) Inhaled nitric oxide reduces ischemia–reperfusion injury in rat lungs from non-heart-beating donors. J Thorac Cardiovasc Surg 132:132–139CrossRef
14.
go back to reference Pinsky DJ, Oz MC, Koga S et al (1994) Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Investig 93:2291–2297CrossRef Pinsky DJ, Oz MC, Koga S et al (1994) Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Investig 93:2291–2297CrossRef
15.
go back to reference Minamiyama Y, Takemura S, Hai S, Suehiro S, Okada S, Funae Y (2007) Nicorandil elevates tissue cGMP levels in a nitric-oxide-independent manner. J Pharmacol Sci 103:33–39CrossRef Minamiyama Y, Takemura S, Hai S, Suehiro S, Okada S, Funae Y (2007) Nicorandil elevates tissue cGMP levels in a nitric-oxide-independent manner. J Pharmacol Sci 103:33–39CrossRef
16.
go back to reference Tajima M, Ishizuka N, Saitoh K, Sakagami H (2008) Nicorandil enhances the effect of endothelial nitric oxide under hypoxia-reoxygenation: role of the KATP channel. Eur J Pharmacol 579:86–92CrossRef Tajima M, Ishizuka N, Saitoh K, Sakagami H (2008) Nicorandil enhances the effect of endothelial nitric oxide under hypoxia-reoxygenation: role of the KATP channel. Eur J Pharmacol 579:86–92CrossRef
17.
go back to reference Furuya A, Kashimoto S, Kumazawa T (2002) Effects of nicorandil on myocardial function and metabolism in the post-ischaemic reperfused heart with or without inhalation anaesthetics. Acta Anaesthesiol Scand 46:24–29CrossRef Furuya A, Kashimoto S, Kumazawa T (2002) Effects of nicorandil on myocardial function and metabolism in the post-ischaemic reperfused heart with or without inhalation anaesthetics. Acta Anaesthesiol Scand 46:24–29CrossRef
Metadata
Title
Nicorandil, a KATP Channel Opener, Attenuates Ischemia–Reperfusion Injury in Isolated Rat Lungs
Authors
Kyoko Abe
Takashi Horiguchi
Keiji Enzan
Yoko Masaki
Toshiaki Nishikawa
Tetsu Kimura
Publication date
01-04-2020
Publisher
Springer US
Published in
Lung / Issue 2/2020
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-020-00339-0

Other articles of this Issue 2/2020

Lung 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine